Dr Philippa O'Brien
Senior Research Officer; Group leader, Cancer Research Program, Garvan Institute of Medical Research; Conjoint Senior Lecturer, Department of Medicine, St Vincent’s Hospital Clinical School, The University of New South Wales; Cancer Institute NSW Fellow
Email: p.obrien 'at' garvan.org.au
Research Group: Ovarian Cancer
Education
1993 PhD, University of Melbourne
1988 BSc (Hons) University of Otago, New Zealand
Awards and Honours
2005 Cancer Institute NSW Career Development and Support Fellowship
1994 Imperial Cancer Research Fund UK Post-Doctoral Fellowship
Publications
Barton CA, Hacker NF, Clark SJ, O’Brien PM (2008) DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109: 129-39
O’Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolyer RA, Zeng Y, Williams Ed, Scurr L, de Fazio A, Quinn DI, Watts CKW, Hacker NF, Henshall SM, Sutherland RL (2008) The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer 98: 1085-93
Barton CA, Clark SJ, Hacker NF, O'Brien PM (2008) Epigenetic markers of ovarian cancer. In “Ovarian Cancer: State of the Art and Future Directions in Translational Research” Coukos G, Berchuck A, Ozols R (Eds) Adv Exp Med Biol 622: 35-51.
Heinzelmann-Schwarz VA, Scolyer RA, Scurry JP, Smith AN, Gardiner-Garden M, Biankin AV, Baron-Hay S, Scott C, Ward RL, Fink D, Hacker NF, Sutherland RL, O'Brien PM. Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. J Clin Pathol 2007; 60(6):622-6
Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 2006; 94:904-913.
Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005; 113(2):276-83.
O'Brien PM, Millan DW, Davis JA, Campo MS. In situ isolation of immunoglobulin sequences expressed by single tumor-infiltrating B cells using laser-assisted microdissection. Mol Biotechnol 2005; 29(2):101-9.
Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM. Overexpression of the cell adhesion molecules DDR1, claudin 3 and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clinical Cancer Research 2004; 10:4427-4436.
Bali A, O'Brien PM, Edwards L, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53 and p21wafl/cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clinical Cancer Research 2004; 10:5168-5177.
O'Brien PM, Campo MS. Papillomaviruses: a correlation between immune evasion and oncogenicity? Trends Microbiol 2003; 11(7):300-5.
Marchetti B, Ashrafi GH, Tsirimonaki E, O’Brien PM, Campo MS. The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface. Oncogene 2002; 21: 7808-7816.
O’Brien PM, Tsirimonaki E, Coomber DWJ, Millan DWM, Davis JA and Campo MS. Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection. Cancer Immunol Immunother 2001; 50: 523-532.
O’Brien PM, Aitken R, O’Neil B, Campo MS. Production of native bovine mAbs by phage display. Proc Natl Acad Sci USA 1999; 96: 640-645.
